Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4309410 | 0.87 | CES2 (0.44) | CES2CES1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2281307 | 0.86 | SMN1; SMN2 (0.35) | PARP1SMN1; SMN2RXFP1MEN1KMT2A | |
| SCHEMBL4312595 | 0.86 | SMN1; SMN2 (0.47) | CES2CES1PARP1SMN1; SMN2MEN1 | |
| SCHEMBL4316039 | 0.86 | CES2 (0.58) | CES2CES1SMN1; SMN2TSHRPDE4A | |
| SCHEMBL4308482 | 0.85 | L3MBTL1 (0.42) | PARP1SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL15956962 | 0.85 | CES2 (0.56) | CES2CES1PARP1SMN1; SMN2MEN1 | |
| SCHEMBL15956605 | 0.84 | SMN1; SMN2 (0.47) | CES2CES1PARP1SMN1; SMN2MEN1 | |
| SCHEMBL3538145 | 0.83 | RAB9A (0.50) | CES2CES1PARP1RXFP1MEN1 | |
| SCHEMBL21387055 | 0.83 | CES2 (0.53) | CES2CES1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15956517 | 0.82 | CES2 (0.59) | CES2SMN1; SMN2MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210101879-A1 | AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-04-08 | — | — | US | disclosed |
| US-20210101879-A1 | AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-04-08 | — | — | US | disclosed |
| EP-3759079-A1 | AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER'S DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-01-06 | — | — | EP | disclosed |
| EP-2137161-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008115552-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008115552-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS | WYETH (US) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210101879-A1 | AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE | APP, BACE1, BACE2 | CES2 2574/4885CES1 781/4885PARP1 4037/4885 |
| US-20090042964-A1 | AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS | BACE1, BACE2, APP | CES2 2959/4885CES1 1257/4885PARP1 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.